Adcock Ingram Holdings Limited

What Adcock Ingram Holdings Limited does

Adcock Ingram Holdings Limited is a South African pharmaceutical manufacturer, marketer, and distributor founded in 1890, publicly listed on the Johannesburg Stock Exchange (JSE:ADJ) and majority-owned by Bidvest Group, with India's Natco Pharma holding a 35.75% minority stake acquired in April 2024 for $226 million. The company ranks 2nd in South Africa's private and public pharmaceutical markets with 10.2% private-market share, reported R9.8 billion turnover as at June 2025, and approximately 2,430 permanent employees. It operates 3 manufacturing facilities in South Africa and 2 in India, supported by 4 finished goods warehouses; 59% of turnover is single-exit-price (SEP) regulated.

The portfolio is organized across three segments: prescription (Rx) medicines covering women's health (menopause hormone therapy patches, tablets, and gel; bacterial vaginosis; endometriosis; osteoporosis), heart health, mental health, pain and inflammation, eye health, and generics; over-the-counter (OTC) consumer brands including Panado, Allergex, Citro-Soda, Myprodol, Epi-max, Cepacol, Compral, and Corenza Para-C; and hospital and critical care products including blood collection and renal dialysis supplies, where the company is South Africa's largest supplier to the private sector. The skin care range includes the Skinoren (azelaic acid) line licensed from LEO Pharmaceutical and the SBR Repair and SBR Protect barrier creams approved by the Allergy Foundation of South Africa.

The business model is B2B sales-led: direct engagement with healthcare professionals via a field sales force supplemented by the RxHCPHub online portal (online ordering, rep connect, adverse event reporting), direct hospital supply, and wholesale distribution through retail pharmacy chains including Clicks and Dis-Chem. The company holds a Level 1 B-BBEE rating — the highest tier — which is a meaningful procurement advantage in South African healthcare tenders. The operating footprint is concentrated in South Africa with adjacent activity in India through manufacturing; the geographic, product, and channel scope are all domestic-South-Africa anchored, with international expansion signaled primarily through the Natco partnership and Indian manufacturing footprint rather than through commercial sales abroad.

Name

Adcock Ingram Holdings Limited

Legal name

Adcock Ingram Limited

Website

https://adcock.com

Company type

Public

Founded year

1890

Operating status

Operating

Headcount range

101–250 employees

Short description

Adcock Ingram is a 130-year-old South African pharmaceutical manufacturer and distributor, ranked 2nd in the domestic market with R9.8 billion turnover, serving hospitals, pharmacies, and healthcare professionals across prescription, OTC, and hospital/critical care segments.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Pharmaceutical manufacturing
• Prescription medicines
• Over-the-counter medicines
• Hospital healthcare supplies
• Consumer healthcare products

Headquarters

HQ city

Midrand

HQ country

South Africa

HQ region

Africa

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Products: Adcock Ingram generates revenue through manufacturing, marketing, sales, and distribution of pharmaceutical products including prescription medicines, over-the-counter (OTC) brands, and hospital/critical care products. The company has a diversified portfolio spanning non-price regulated healthcare, consumer products, branded and generic prescription medicines.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Adcock Ingram manufactures, markets, sells, and distributes a diversified portfolio of branded and generic prescription medicines, over-the-counter (OTC) consumer healthcare brands, and hospital and critical care products (including renal dialysis supplies). The portfolio spans therapeutic areas such as women's health, heart health, eye health, skin care, mental health, pain and inflammation, and generic medicines, distributed through direct sales to healthcare professionals and hospitals and via pharmacy retail and wholesale channels in South Africa.

Product overview

Adcock Ingram Holdings Limited is a South African pharmaceutical company (founded 1890/1891) ranked 2nd in the private and public pharmaceutical market with a 10.2% market share in the private market, holding a Level 1 B-BBEE rating. The company manufactures, markets, sells, and distributes a diversified portfolio of healthcare products. The portfolio comprises three interconnected layers: (1) Prescription/Branded Rx medicines covering heart health, mental health, pain/inflammation, and women's health (menopause with MHT patches/tablets/gel, osteoporosis, bacterial vaginosis, urinary); (2) Over-the-Counter (OTC) consumer brands including Panado, Allergex, Citro-Soda, Myprodol, Epi-max, Cepacol, and generic equivalents; (3) Hospital and critical care products (blood collection, renal dialysis), where Adcock Ingram is the largest supplier in South Africa. Therapeutic areas span women's health, skin care (Skinoren, SBR Repair, SBR Protect for acne, eczema, psoriasis, rosacea), heart health, generic medicines, eye health, mental health, and pain/inflammation. The company operates 3 manufacturing facilities in South Africa and 2 in India, with 8 finished goods warehouses and a turnover of R1.8 billion (as at June 2025), with 59% from single exit price (SEP) regulated products.

Differentiator

Problem solved

Functional benefit

Brands

• Adcock Ingram Generics: Extensive range of generic medicines that are as effective, safe and of the same quality as originator medicines.
• Adcock Ingram

Products and services

• Prescription Medicines Portfolio Adcock Ingram's branded and generic prescription (Rx) portfolio covering therapeutic areas including heart health, mental health, pain and inflammation, and women's health conditions including menopause, osteoporosis, bacterial vaginosis, and urinary health. Sold through healthcare professionals, hospitals, and pharmacies in South Africa.
• Over-the-Counter (OTC) Consumer Brands OTC consumer healthcare brands available without prescription, including Panado (analgesic), Allergex (antihistamine), Citro-Soda (antacid), Myprodol (analgesic), Epi-max (topical), Cepacol (throat/mouth), Bioplus, Adco-Mayogel, Vita-thion, Libiton, Corenza Para-C, and Compral, spanning pain, allergy, digestive, and skincare categories. Distributed through retail pharmacies.
• Hospital and Critical Care Products Hospital and critical care products including blood collection and renal dialysis supplies. Adcock Ingram is positioned as South Africa's largest supplier of hospital and critical care products to the private sector.
• Menopause Hormone Therapy (MHT) Patches Transdermal menopause hormone therapy patches using Dot Matrix technology for sustained delivery of active ingredients through the skin. Designed for discrete, cosmetically acceptable application with lower hormone doses than tablet alternatives.
• Menopause Hormone Therapy (MHT) Tablets Menopause hormone therapy tablets for management of menopausal symptoms, available in different formulations for women with and without a uterus and for peri- and post-menopausal women.
• Menopause Hormone Therapy (MHT) Gel Oestrogen gel applied daily to the arm for relief of menopausal symptoms, offering transdermal hormone delivery as an alternative to tablets or patches.
• Skinoren Acne Cream and Gel Topical azelaic acid formulation (20% cream / 15% gel) for the treatment of acne and rosacea. Available as both prescription S1 medicine (cream) and over-the-counter (gel). Licensed from LEO Pharmaceutical Products and promoted under permission from Bayer (Pty) Ltd.
• SBR Repair Cream High-fat cream with skin-identical lipids for repairing and restoring the skin barrier in dry skin, atopic dermatitis/eczema, and psoriasis. Approved by the Allergy Foundation of South Africa and available in pharmacies, Clicks, and Dis-Chem.
• SBR Protect Cream High-lipid (70%) protective cream for instant hydration and skin barrier protection, indicated for dry skin, eczema, and psoriasis. Approved by the Allergy Foundation of South Africa. Available in 30 g and 100 g tubes.
• Adcock Ingram Generics Range of generic medicines positioned as equally effective, safe, and of the same quality as originator (branded) medicines, offered at more accessible price points across multiple therapeutic areas.
• Eye Health Products Treatment solutions for various diseases and disorders of the eye including dry eye, eye infections, inflammation, allergic conjunctivitis, and glaucoma.
• Heart Health Products Cardiovascular portfolio encompassing treatments for hypertension, cholesterol, metabolic syndrome, and diabetes.
• Mental Health Products Pharmaceutical products addressing mental health conditions as part of Adcock Ingram's therapeutic portfolio.
• Pain and Inflammation Products Analgesic and anti-inflammatory products including prescription and OTC brands such as Panado, Myprodol, and Compral.
• Women's Health Portfolio Women's health portfolio covering bacterial vaginosis, endometriosis, menopause (including MHT patches, tablets, and gel), and osteoporosis, addressing both short-term and long-term women's health needs.
• Skin Care Portfolio Dermatological range treating acne, psoriasis, skin infections, eczema, rosacea, and general dry skin, marketed under brands including Skinoren, SBR Repair, and SBR Protect.

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Market position

Strengths4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/AdcockIngramHealthcare
• LinkedInlinkedin.com/company/adcock-ingram

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adcock Ingram Holdings Limited